Dr. Goldberg is Clinical Professor of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York and Director, Affective Disorders Research Program, Silver Hill Hospital, New Canaan, Connecticut.
Joseph F. Goldberg, MD, discusses future treatments targeting the glutamate system, such as ketamine, for treatment-resistant mood disorders.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
